Preclinical profiling of the immunogenicity of a two-component subunit malaria vaccine candidate based on virosome technology (Publications)
anti-peptide responses, augmenting the value of this system for the development of a multivalent malaria vaccine
Estimation of the sequestered parasite load in severe malaria patients using both host and parasite markers (Publications)
The virulence of the malaria parasite Plasmodium falciparum is due, in part, to its ability to cytoadhere in deep vascular beds. Our inability to quantify the load of sequestered parasites hampers our [...] patterns of peripheral parasite densities in a series of 22 patients with severe Plasmodium falciparum malaria. The markers comprised the host factors: haematocrit, circulating host DNA, sTNF-R75 and parasite
<em>In vitro</em> screening of traditional South African malaria remedies against <em>Trypanosoma brucei rhodesiense</em>, <em>Trypanosoma cruzi,... (Publications)
Three hundred extracts were prepared from plants traditionally used in South Africa to treat malaria and screened IN VITRO for activity against TRYPANOSOMA BRUCEI RHODESIENSE, TRYPANOSOMA CRUZI, LEISHMANIA
Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunization (Publications)
BACKGROUND: The RTS,S/AS01(E) malaria candidate vaccine is being developed for immunization of African infants through the Expanded Program of Immunization (EPI). METHODS: This phase 2, randomized, open [...] registration. ClinicalTrials.gov identifier: NCT00436007 . GlaxoSmithKline study ID number: 106369 (Malaria-050)